Home » Stocks » LIXT

Lixte Biotechnology Holdings, Inc. (LIXT)

Stock Price: $2.82 USD 0.00 (0.00%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $2.80 -0.02 (-0.71%) May 7, 5:32 PM
Market Cap 37.91M
Revenue (ttm) n/a
Net Income (ttm) -3.26M
Shares Out 13.54M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $2.82
Previous Close $2.82
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.82
Day's Range 2.70 - 2.88
Day's Volume 106,090
52-Week Range 2.36 - 7.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments

3 days ago - GlobeNewsWire

EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacolog...

3 weeks ago - GlobeNewsWire

EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in can...

2 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology ...

2 months ago - Business Wire

JERSEY CITY, N.J., March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a Registered Direct Offering...

2 months ago - PRNewsWire

East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer t...

2 months ago - GlobeNewsWire

Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma ...

Other stocks mentioned: ATNX, MORF
2 months ago - Benzinga

East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer...

2 months ago - GlobeNewsWire

Lixte Biotechnology (LIXT) stock is heading higher on Friday with heavy trading of shares despite a lack of news concerning the company. The post LIXT Stock: 8 Things to Know About Lixte Biotechnology A...

2 months ago - InvestorPlace

EAST SETAUKET, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc...

2 months ago - GlobeNewsWire

EAST SETAUKET, NY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc...

3 months ago - GlobeNewsWire

About LIXT

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically ac... [Read more...]

Industry
Biotechnology
Founded
2005
Stock Exchange
NASDAQ
Ticker Symbol
LIXT
Full Company Profile

Financial Performance

Financial Statements